Bayer Stock Edges Higher on Technicals but Faces a Storm of Legal and Trade Tests

Bayer shares edge above 50-day moving average but face pivotal US Supreme Court ruling, German healthcare reform, and trade probe. Analysts split with UBS buy at €52 vs Jefferies hold at €40.

Bayer shares scraped past the 50-day moving average at Friday’s close, but the modest technical win may be fleeting. The stock finished at €37.81—just one cent above the momentum gauge—after a daily gain of roughly 2% that capped a weekly advance of 4.85%. Yet the real action lies not on the charts but in a crowded calendar of legal and political events that could swing the shares sharply in either direction.

The most immediate flashpoint is the US Supreme Court, which is expected to rule by the end of June on whether federal law preempts state-level warning requirements for Roundup. Bank of America, citing a legal expert, pegs the probability of a favorable decision for Bayer at roughly 70%. A win would significantly reduce the legal overhang; a loss would push the stock toward the 200-day moving average at €36.22. Either way, the decision is only the first of three pivotal dates. In July, a Missouri court will hold a final hearing on a proposed multibillion-dollar settlement on the 9th, and the Bundestag is scheduled to vote on the GKV healthcare reform on the 10th—a reform that Washington has already flagged as problematic.

That reform lies at the heart of a separate risk: a US trade investigation under Section 301 of the Trade Act of 1974. US Trade Representative Jamieson Greer has launched a probe into whether Germany systematically undervalues innovative medicines, forcing US patients to shoulder a disproportionate share of global R&D costs. Berlin’s plan to close a €20 billion hole in statutory health insurance by cutting drug spending has alarmed Greer, who said he is “concerned” about further reductions. The investigation could pave the way for punitive tariffs on German pharmaceutical exports—a direct hit to Bayer’s competitiveness. A hearing on potential trade penalties is scheduled for September 2026.

Meanwhile, Bayer continues to execute on its pipeline. Last week it closed the acquisition of Perfuse Therapeutics, paying an upfront $300 million and promising up to $2.45 billion in milestone payments. The deal gives Bayer full rights to PER-001, an intravitreal implant in Phase II for glaucoma and diabetic retinopathy. The company is also making operational headway: its AI-driven production facility in Leverkusen recently won a major industry award. Management expects the technology to cut manufacturing costs by 8% to 12% and generate an additional €800 million to €1.2 billion in gross profit over the next five years, with a return on capital that significantly beats the sector average.

Analysts remain split on the stock’s trajectory. UBS recommends buying with a €52 target, while Jefferies takes a more cautious stance with a “hold” rating and a €40 price objective. The divergence reflects the uncertainty surrounding the legal and trade fronts. On the one hand, a Supreme Court victory could clear the way for a definitive settlement and send the shares toward the 52-week high of roughly €50. On the other, a negative decision combined with escalating trade tensions could keep the stock trapped below the 200-day line for months.

For now, Bayer sits at a crossroads. The technical picture is neutral, the legal calendar is dense, and the trade probe introduces a wildcard that no earnings report can address. Investors will be watching the Supreme Court’s next move with as much attention as they watch the opening bell.